Percentage of Her2 positive cells in immunohistochemistry-equivocal (2+) invasive breast cancer and its significance as a predictive value for the amplification status

被引：0
|
作者：
Marras, V. [1 ]
Satta, G. [1 ]
Fedeli, M. A. [1 ]
Trombetta, M. [1 ]
Lako, K. [1 ]
Meloni, M. [1 ]
Fara, A. M. [1 ]
Camboni, A. C. [1 ]
Doneddu, V. [1 ]
Manca, A. [1 ]
Tanda, F. [1 ]
机构：
[1] AOU Sassari, UO Anat Patol, Sassari, Italy
来源：
VIRCHOWS ARCHIV | 2017年 / 471卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
PS-01-034
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [31] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    MODERN PATHOLOGY, 2019, 32
  • [32] Percentage of HER2 immunohistochemistry complete membrane staining is not significantly associated with response to neoadjuvant therapy in HER2 positive breast cancer
    Li, Xiaoxian
    Zhao, Jing
    Zhang, Chao
    Li, Zaibo
    LABORATORY INVESTIGATION, 2019, 99
  • [33] Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting
    Wu, Ziping
    Xu, Shuguang
    Zhou, Liheng
    Yin, Wenjin
    Lin, Yanpin
    Du, Yueyao
    Wang, Yaohui
    Jiang, Yiwei
    Yin, Kai
    Zhang, Jie
    Lu, Jinsong
    ONCOTARGETS AND THERAPY, 2018, 11 : 801 - 808
  • [34] The frequency of HER2 amplification and the percentage of membrane staining in HER2 2+invasive carcinomas of the breast Reply
    Polonia, Antonio
    Canelas, Carolina
    Caramelo, Ana
    VIRCHOWS ARCHIV, 2022, 481 (02) : 329 - 330
  • [35] Biological analysis of HER2 equivocal (2+) cases in primary breast cancer.
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Nakano, Masahiro
    Fujisue, Mamiko
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: A study at a tertiary cancer center
    Murthy, Sudha S.
    Sandhya, D. G.
    Ahmed, Faiq
    Goud, K. Iravathy
    Dayal, Monal
    Suseela, K.
    Rajappa, Senthil J.
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2011, 54 (03) : 532 - 538
  • [37] Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry
    Tsai, Yi-Fang
    Hsu, Chih-Yi
    Chiu, Yun-Ning
    Huang, Chi-Cheng
    Chou, Shih-Hsiang
    Lin, Yen-Shu
    Chao, Ta-Chung
    Liu, Chun-Yu
    Chiu, Jen-Hwey
    Tseng, Ling-Ming
    BREAST CANCER-TARGETS AND THERAPY, 2025, 17
  • [38] Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive for false-negative immunohistochemistry?
    Barrett, Ciara
    Magee, Hilary
    O'Toole, Denise
    Daly, Sinead
    Jeffers, Michael
    JOURNAL OF CLINICAL PATHOLOGY, 2007, 60 (06) : 690 - 693
  • [39] Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
    Stocker, Albina
    Trojan, Andreas
    Elfgen, Constanze
    Hilbers, Marie-Louis
    Moskovszky, Linda
    Varga, Zsuzsanna
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (02) : 311 - 319
  • [40] Differential prognostic value of positive HER2 status determined by immunohistochemistry or fluorescence in situ hybridization in breast cancer
    Albina Stocker
    Andreas Trojan
    Constanze Elfgen
    Marie-Louis Hilbers
    Linda Moskovszky
    Zsuzsanna Varga
    Breast Cancer Research and Treatment, 2020, 183 : 311 - 319
12345